Related Experiment Video
Updated: Apr 14, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.8K
Past, present, and future for biologic intervention in atopic dermatitis
M D Howell1, M L Parker1, T Mustelin1
1MedImmune, LLC, Gaithersburg, MD, USA.
Allergy
|April 17, 2015
Summary
Atopic dermatitis (AD) treatments aim to manage inflammation and skin barrier function, but current options offer temporary relief and side effects. New monoclonal antibody therapies show promise by targeting specific disease pathways.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) significantly impacts quality of life, affecting 25% of children and 10% of adults.
- Current AD management involves combination therapies to suppress inflammation, restore skin barrier function, and prevent infections.
- Existing treatments provide temporary relief and may cause significant side effects with long-term use.
Purpose of the Study:
- To review the biological pathways implicated in atopic dermatitis pathogenesis.
- To provide an overview of emerging monoclonal antibody therapies for atopic dermatitis.
- To discuss the current state of therapeutic development for AD.
Main Methods:
- Literature review of existing atopic dermatitis treatments.
- Analysis of immunological and molecular pathways in AD.
- Evaluation of antibody therapies in clinical development for AD.
Main Results:
- Previous antibody therapies for inflammatory diseases showed limited clinical benefit in AD.
- Monoclonal antibodies targeting specific immune and molecular pathways are under development.
- These targeted therapies offer potential for improved efficacy and safety in AD management.
Conclusions:
- Atopic dermatitis requires innovative therapeutic strategies beyond current management options.
- Targeted monoclonal antibody therapies represent a promising advancement in treating AD.
- Further research into specific disease pathways will guide the development of next-generation AD therapeutics.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
989
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
989
01:28Drug Products: Biologics, Biosimilars and Interchangeables
360
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
360
01:29Microorganisms in Medicine and Therapeutics
1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
804
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
804
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
01:20Asthma: Pathogenesis and Management
1.7K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K